The restaging of breast cancer with PET/CT
Keywords:
Positron-emission tomography, breast neoplasms, neoplasm stagingAbstract
Breast cancer represents the most frequent malignancy in women, accounting for 26% of all female cancers, according to international publications. During the period 2000 to 2006, more than 10,000 breast cancer deaths were recorded in Colombia. Greater availability of advanced technology for image based diagnosis buttresses an improved staging process for patients with this disease. Positron emission tomography (PET) has made an enormous impact on the restaging and metastasis detection in cancer patients. A case study is presented of a breast cancer patient suspected of relapse, subsequently confirmed by PET/CT which revealed lymph node and bone metastasis.
Author Biography
Alejandro Martí, Instituto Nacional de Cancerología
Grupo de Medicina Nuclear, Instituto Nacional de Cancerología, Bogotá D. C., Colombia
References
Wahl R, Beanlands R. Principles and practice of PET and PET/CT. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.
International Atomic Energy Agency (IAEA). A Guide to Clinical PET in Oncology: Improving Clinical Management of Cancer Patients. Vienna: IAEA; 2008.
Pezeshk P, Sadow CA, Winalski CS, et al. Usefulness of 18F-FDG PET-directed skeletal biopsy for metastatic neoplasm. Acad Radiol. 2006;13:1011-5.
https://doi.org/10.1016/j.acra.2006.05.005
Hain SF, O'doherty MJ, Bingham J, et al. Can FDG PET be used to successfully direct preoperative biopsy of soft tissue tumours? Nucl Med Commun. 2003;24:1139-43.
https://doi.org/10.1097/00006231-200311000-00003
República de Colombia. Instituto Nacional de Cancerología (INC). Anuario Estadístico 2008. Bogotá: INC; 2009.
Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71-96.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Todos los derechos reservados.
